Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium (177Lu) Oxodotreotide in Advanced Gastroenteropancreatic Neuroendocrine Tumors
NCT05884255Phase 3Recruiting
- Sponsor
- Hengrui
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Hengrui. Started Jul 2023; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT05884255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05884255.